Carisma Therapeutics Inc. buy melinda
Start price
31.10.18
/
50%
€26.34
Target price
07.11.18
€31.57
Performance (%)
6.16%
End price
07.11.18
€27.96
Summary
This prediction ended on 07.11.18 with a price of €27.96. With a performance of 6.16%, the BUY prediction by melinda for Carisma Therapeutics Inc. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Carisma Therapeutics Inc. | -8.801% | -8.801% | -80.143% | -94.428% |
iShares Core DAX® | -3.429% | 3.133% | 15.455% | 14.827% |
iShares Nasdaq 100 | -6.121% | -1.433% | 16.794% | 27.167% |
iShares Nikkei 225® | -7.364% | 1.018% | 8.293% | -2.680% |
iShares S&P 500 | -4.366% | 0.247% | 18.541% | 32.687% |
According to melinda what are the pros and cons of Carisma Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Sesen Bio Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 14/11 Publication de résultats
Develops protein therapeutics to treat eye diseases
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics.
It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells.
The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics.
It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells.
The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Nombre d'employés : 17 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Carisma Therapeutics Inc.
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€16.58
16.10.21
16.10.21
-
16.10.22
16.10.22
22.56%
24.10.21
24.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.90
16.10.21
16.10.21
-
16.10.22
16.10.22
-
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.90
16.10.21
16.10.21
-
16.10.22
16.10.22
-
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.90
16.10.21
16.10.21
-
16.10.22
16.10.22
-
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€15.44
12.10.21
12.10.21
-
12.10.22
12.10.22
7.38%
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€73.80
17.06.21
17.06.21
€50.00
17.06.22
17.06.22
-66.50%
17.08.21
17.08.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€18.58
21.08.20
21.08.20
€30.00
04.11.21
04.11.21
297.12%
17.06.21
17.06.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€34.10
21.05.19
21.05.19
€45.10
21.08.20
21.08.20
-45.50%
21.08.20
21.08.20
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€22.73
05.05.19
05.05.19
€39.69
20.05.19
20.05.19
34.13%
20.05.19
20.05.19
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€13.35
19.11.17
19.11.17
€21.65
03.01.18
03.01.18
16.91%
03.01.18
03.01.18
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€47.45
10.07.16
10.07.16
€54.12
25.07.16
25.07.16
20.50%
25.07.16
25.07.16
Could be worthwhile Investment >10% per year